The Spinal Muscular Atrophy Health Index: A novel outcome for measuring how a patient feels and functions

被引:24
作者
Zizzi, Christine E. [1 ,2 ]
Luebbe, Elizabeth [1 ]
Mongiovi, Phillip [1 ]
Hunter, Michael [3 ]
Dilek, Nuran [1 ]
Garland, Connie [4 ]
Ciafaloni, Emma [1 ]
Zaidman, Craig M. [5 ]
Kissel, John T. [6 ]
McDermott, Michael P. [1 ,2 ,7 ]
Johnson, Nicholas [8 ]
Sansone, Valeria [9 ]
Heatwole, Chad R. [1 ,2 ]
机构
[1] Univ Rochester, Dept Neurol, 265 Crittenden Blvd,CU 420694, Rochester, NY 14642 USA
[2] Ctr Hlth & Technol, Rochester, NY USA
[3] Univ Calif Irvine, Dept Neurol, Orange, CA 92668 USA
[4] Indiana Univ Sch Med, Dept Pediat Neurol Surg, Indianapolis, IN 46202 USA
[5] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA
[6] Ohio State Univ, Dept Neurol, Wexner Med Ctr, Columbus, OH 43210 USA
[7] Univ Rochester, Dept Biostat & Computat Biol, Rochester, NY USA
[8] Virginia Commonwealth Univ, Dept Neurol, Richmond, VA USA
[9] NEuroMuscular Omnictr NEMO, Piazza Osped Maggiore 3, Milan, Italy
关键词
disease burden; patient‐ reported outcome measure; quality of life; spinal muscular atrophy; symptom assessment; therapeutic trial; DISEASE; GENE;
D O I
10.1002/mus.27223
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction The Spinal Muscular Atrophy Health Index (SMA-HI) is a multifaceted, disease-specific, patient-reported outcome to measure an SMA patient's perception of their disease burden. In preparation for upcoming therapeutic trials, we examine the validity, reliability, and usability of the SMA-HI in adults, teenagers, and children with SMA. Methods Using data from a cross-sectional study of 359 international adult patients with SMA, we identified the most relevant symptoms to include in the SMA-HI. We utilized factor analysis, patient interviews with adults and minors (age 8-15 years), known-group validity testing, and test-retest reliability assessments to evaluate and refine the SMA-HI. Results The SMA-HI measures overall disease burden and 15 areas of SMA health. Fifteen adult patients and five patients, age 8 to 15 years, participated in semistructured qualitative interviews and found the SMA-HI to be comprehensive, easily completed, and to have clear meaning. The final SMA-HI and its subscales demonstrated good internal consistency (Cronbach alpha = 0.77-0.96), high test-retest reliability (intraclass correlation coefficient = 0.60-0.96), and an ability to differentiate between SMA groups with different disease severities affecting areas such as employment and ambulation (P < .0001 for both). Discussion This research provides evidence that the SMA-HI is a valid, relevant, and reliable outcome measure to assess multifaceted patient-reported disease burden in older children, teenagers, and adults with SMA. The SMA-HI provides an opportunity for researchers and clinicians to measure a SMA patient's perception of their health and determine relevant changes in response to therapeutic intervention or disease progression.
引用
收藏
页码:837 / 844
页数:8
相关论文
共 13 条
[1]  
Borkowska J, 2002, FOLIA NEUROPATHOL, V40, P19
[2]   REPRODUCIBILITY AND RESPONSIVENESS OF HEALTH-STATUS MEASURES - STATISTICS AND STRATEGIES FOR EVALUATION [J].
DEYO, RA ;
DIEHR, P ;
PATRICK, DL .
CONTROLLED CLINICAL TRIALS, 1991, 12 (04) :S142-S158
[3]   MYOTONIC DYSTROPHY HEALTH INDEX: INITIAL EVALUATION OF A DISEASE-SPECIFIC OUTCOME MEASURE [J].
Heatwole, Chad ;
Bode, Rita ;
Johnson, Nicholas ;
Dekdebrun, Jeanne ;
Dilek, Nuran ;
Heatwole, Mark ;
Hilbert, James E. ;
Luebbe, Elizabeth ;
Martens, William ;
Mcdermott, Michael P. ;
Rothrock, Nan ;
Thornton, Charles ;
Vickrey, Barbara G. ;
Victorson, David ;
Moxley, Richard, III .
MUSCLE & NERVE, 2014, 49 (06) :906-914
[4]  
Hunter Michael, 2016, J Neuromuscul Dis, V3, P425
[5]  
International SMA Patient Registry Indiana University, 2015, SMAREGISTRYIUEDU ACC
[6]   The Charcot-Marie-Tooth Health Index: Evaluation of a Patient-Reported Outcome [J].
Johnson, Nicholas E. ;
Heatwole, Chad ;
Creigh, Peter ;
McDermott, Michael P. ;
Dilek, Nuran ;
Hung, Man ;
Bounsanga, Jerry ;
Tang, Wan ;
Shy, Michael E. ;
Herrmann, David N. .
ANNALS OF NEUROLOGY, 2018, 84 (02) :225-233
[7]  
McColl E, 2005, ASSESSING QUALITY LI, P9
[8]   GENE FOR CHRONIC PROXIMAL SPINAL MUSCULAR ATROPHIES MAPS TO CHROMOSOME-5Q [J].
MELKI, J ;
ABDELHAK, S ;
SHETH, P ;
BACHELOT, MF ;
BURLET, P ;
MARCADET, A ;
AICARDI, J ;
BAROIS, A ;
CARRIERE, JP ;
FARDEAU, M ;
FONTAN, D ;
PONSOT, G ;
BILLETTE, T ;
ANGELINI, C ;
BARBOSA, C ;
FERRIERE, G ;
LANZI, G ;
OTTOLINI, A ;
BABRON, MC ;
COHEN, D ;
HANAUER, A ;
CLERGETDARPOUX, F ;
LATHROP, M ;
MUNNICH, A ;
FREZAL, J .
NATURE, 1990, 344 (6268) :767-768
[9]   Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy [J].
Mendell, J. R. ;
Al-Zaidy, S. ;
Shell, R. ;
Arnold, W. D. ;
Rodino-Klapac, L. R. ;
Prior, T. W. ;
Lowes, L. ;
Alfano, L. ;
Berry, K. ;
Church, K. ;
Kissel, J. T. ;
Nagendran, S. ;
L'Italien, J. ;
Sproule, D. M. ;
Wells, C. ;
Cardenas, J. A. ;
Heitzer, M. D. ;
Kaspar, A. ;
Corcoran, S. ;
Braun, L. ;
Likhite, S. ;
Miranda, C. ;
Meyer, K. ;
Foust, K. D. ;
Burghes, A. H. M. ;
Kaspar, B. K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (18) :1713-1722
[10]   Patient Reported Impact of Symptoms in Spinal Muscular Atrophy (PRISM-SMA) [J].
Mongiovi, Phillip ;
Dilek, Nuran ;
Garland, Connie ;
Hunter, Michael ;
Kissel, John T. ;
Luebbe, Elizabeth ;
McDermott, Michael P. ;
Johnson, Nicholas ;
Heatwole, Chad .
NEUROLOGY, 2018, 91 (13) :E1206-E1214